Study S002621

Effect of a Dietary Supplement (FitLine TopShape) on the Incretin Response

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07240246
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 40
Start: 2025-10-24
Primary completion: 2026-03-11
Lead sponsor: FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation
Conditions: GLP-1; Obesity &Amp; Overweight; Dietary Supplement
Interventions: DIETARY_SUPPLEMENT:Intervention: Dietary Supplement with Plant Extracts; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

GLP-1 secretion [12 weeks]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006079	What is the pipeline for future medications for obesity? Melson E, International journal of obesity (2005)	2025	Other trial	PMID 38302593 DOI	registry reference BACKGROUND:38302593
R0005733	Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Gleason PP, Journal of managed care & specialty pharmacy	2024	Nonrandomized study	PMID 38717042 DOI	registry reference BACKGROUND:38717042
R0018819	Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Gabe MBN, Diabetes, obesity & metabolism	2024	Randomized trial	PMID 39082206 DOI	registry reference BACKGROUND:39082206
R0010847	Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control. Stenlid R, Frontiers in endocrinology	2023	Randomized trial	PMID 38027106 DOI	registry reference BACKGROUND:38027106
R0022314	Diets and drugs for weight loss and health in obesity - An update. Aaseth J, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2021	Narrative review	PMID 34082399 DOI	registry reference BACKGROUND:34082399
R0024139	Glucagon-like peptide 1 (GLP-1). Müller TD, Molecular metabolism	2019	Preclinical	PMID 31767182 DOI	registry reference BACKGROUND:31767182